Sanara MedTech Business Summary

Sanara MedTech Inc. (SMTI) operates as a pure-play surgical solutions provider, generating revenue primarily through the commercialization of advanced wound care and bone fusion products. Following a strategic realignment in late 2025 that discontinued its Tissue Health Plus segment, the company focuses on high-margin (90%+) surgical technologies, including its flagship CellerateRX Surgical Activated Collagen and the BIASURGE no-rinse irrigation solution. Sanara utilizes a robust distribution network of over 400 contracted representatives to sell into more than 1,400 healthcare facilities across North America. In the competitive landscape, Sanara contends with established medical technology firms such as MiMedx Group (MDXG), Bioventus (BVS), and SiBone (SIBN). The company distinguishes itself through a specialized focus on surgical site biofilm management and a pipeline of transformative products like OsStic, a synthetic injectable bone adhesive slated for a 2027 commercial launch. Leadership is currently spearheaded by President and CEO Seth Yon, who assumed the role in September 2025 after driving a 53% three-year revenue CAGR as the company’s Chief Commercial Officer. He is supported by Executive Chairman Ron Nixon, the former CEO who orchestrated Sanara’s evolution from its predecessor, Wound Management Technologies. The executive suite includes CFO Elizabeth Taylor, appointed in January 2025 with a background in private equity and healthcare finance, and COO Jake Waldrop, who joined in 2024 from Trilliant Surgical. Technical innovation is led by Chief R&D Officer Nina Bionda, Ph.D., who oversees the development of the company’s surgical and wound care portfolio. Notable governance and investment support come from board member Eric Major, the former CEO of Stryker Spine and founder of K2M, and significant institutional backing from Baird Trust Company, which maintains an 8.5% beneficial ownership stake as of early 2026.